Menu Search
Equities

Formycon AG

FYBX:GER

Formycon AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)46.85
  • Today's Change0.35 / 0.75%
  • Shares traded6.07k
  • 1 Year change-23.94%
  • Beta0.6291
Data delayed at least 15 minutes, as of Nov 22 2024 16:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Formycon AG grew revenues 82.83% from 42.50m to 77.70m while net income improved 110.59% from 35.99m to 75.80m.
Gross margin12.46%
Net profit margin105.09%
Operating margin-41.39%
Return on assets6.87%
Return on equity12.73%
Return on investment7.37%
More ▼

Cash flow in EURView more

In 2023, Formycon AG increased its cash reserves by 175.31%, or 17.22m. Cash Flow from Financing totalled 44.44m or 57.20% of revenues. In addition the company used 9.85m for operations while cash used for investing totalled 17.38m.
Cash flow per share3.95
Price/Cash flow per share12.45
Book value per share32.64
Tangible book value per share0.3878
More ▼

Balance sheet in EURView more

Formycon AG uses little debt in its capital structure as supported by a debt to capital ratio of 1.85%.
Current ratio2.10
Quick ratio2.06
Total debt/total equity0.0189
Total debt/total capital0.0185
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.